You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美股異動|再鼎醫藥盤前升1% 艾加莫德新劑型獲FDA批准 機構看好
再鼎醫藥(ZLAB.US)盤前升1.02%,報30.69美元。消息面上,4月11日,再鼎醫藥合作伙伴argenx公司宣佈,美國FDA已正式批准了艾加莫德預充式皮下注射劑型,用於治療乙酰膽鹼受體(AChR)抗體陽性的全身型重症肌無力(gMG)成人患者和慢性炎性脱髓鞘性多發性神經根神經病(CIDP)成人患者。再鼎醫藥稱將於2025年在國內遞交艾加莫德預充式皮下注射劑型的上市申請。德邦證券發研報指,艾加莫德有望治療多種由致病性IgG抗體介導的嚴重的自身免疫性疾病,且正在多種自身免疫性疾病適應證中進行探索評估,包括TED、LN等大適應症,該行認為其潛在空間不可小覷,有望成為新一代自免領域大單品。預計公司25-27年的收入為5.64/8.35/13.57億美元,增速為41.35%/48.1%/62.5%。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account